{"disease":{"id":"carcinoma-of-cervix","name":"Carcinoma of cervix","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"bevacizumab","indication_name":"Carcinoma of cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avastin","generic_name":"bevacizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":82,"revenue":"2100","mechanism":"Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors."},{"drug_id":"avastin","indication_name":"Carcinoma of cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avastin","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"zirabev","indication_name":"Carcinoma of cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bevacizumab","generic_name":"Bevacizumab-Bvzr","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular Endothelial Growth Factor (VEGF)","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR."}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03382158","title":"International PPB/DICER1 Registry","phase":"","overall_status":"RECRUITING","enrollment_count":3400,"lead_sponsor_name":"Children's Hospitals and Clinics of Minnesota","has_results":false},{"nct_id":"NCT03010150","title":"Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":471,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04517019","title":"Randomised Trial Evaluating the Benefit of a Fitness Tracker Based Workout During Radiotherapy","phase":"NA","overall_status":"UNKNOWN","enrollment_count":201,"lead_sponsor_name":"University Hospital Tuebingen","has_results":false},{"nct_id":"NCT05267834","title":"Adenocarcinoma of the Uterine Cervix and HPV","phase":"","overall_status":"COMPLETED","enrollment_count":148,"lead_sponsor_name":"Università Politecnica delle Marche","has_results":false},{"nct_id":"NCT03589339","title":"NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":145,"lead_sponsor_name":"Nanobiotix","has_results":false},{"nct_id":"NCT05461430","title":"Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)","phase":"","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Travera Inc","has_results":false},{"nct_id":"NCT05975593","title":"MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT03894618","title":"SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Shattuck Labs, Inc.","has_results":true},{"nct_id":"NCT05521997","title":"Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":42,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT03357757","title":"Avelumab With Valproic Acid in Virus-associated Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"AHS Cancer Control Alberta","has_results":false},{"nct_id":"NCT06810895","title":"Evaluation of AK104 (Cadonilimab) Combined with Chemotherapy for Recurrent or Metastatic Small Cell Neuroendocrine Carcinoma of the Cervix","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":20,"lead_sponsor_name":"Ding Ma","has_results":false},{"nct_id":"NCT07435376","title":"Intra-lesional Tumor Boost for Bulky Cervical Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":17,"lead_sponsor_name":"Seoul National University Bundang Hospital","has_results":false},{"nct_id":"NCT03644342","title":"Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Michelle S Ludwig","has_results":true}],"total":13},"guidelines":[],"source":"Drug Landscape verified database"}